灯盏花素联合参附注射液治疗阳气虚衰型急性冠脉综合征随机平行对照研究

Injection Therapy Breviscapine Joint Participation Yang Qi Decline Acute Coronary Syndrome Randomized Parallel Group Study Note

[目的]观察灯盏花素联合参附注射液治疗阳气虚衰型急性冠脉综合征疗效。[方法]使用随机平行对照方法,将72例住院患者按就诊顺序编号随机分为两组。对照组36例美托洛尔12.5mg/次,2次/d,口服;拜阿司匹灵100mg/次,1次/d;贝那普利10mg/次,1次/d;阿托伐他汀10mg/次,1次/d;单硝酸异山梨酯40mg/次,1次/d。治疗组36例灯盏花素20mL+5%葡萄糖注射液250mL,静滴,1次/d;参附注射液50mL+5%葡萄糖注射液250mL,静滴,1次/d。西药治疗同对照组。连续治疗14d为1疗程。观察临床症状、心电图、BNP改善情况及心血管事件发生情况(包括心绞痛恶化加重再次住院,发生心肌梗死,死亡)。治疗1疗程,判定疗效。随访3个月,比较两组再入院人次及症状再发人次。[结果]治疗组显效18例,有效14例,无效4例,总有效率88.89%。对照组显效9例,有效20例,无效7例,总有效率80.56%。治疗组疗效优于对照组(P<0.05)。BNP两组均有改善(P<0.05),治疗组改善优于对照组(P<0.05)。随访3个月内再入院人次及症状再发人次治疗组低于对照组(P<0.05)。[结论]灯盏花素联合参附注射液治疗阳气虚衰型急性冠脉综合征效果显著,不良反应少,值得推广使用。

[ Objective ] Breviscapine combined treatment Shenfu Yang Qi decline acute coronary syndrome . [ Methods ] Random parallel control method, 72 cases of hospitalized patients were randomly divided into two treatment sequence number. A control group of 36 patients with metoprolol , 12.Stag / times, 2 times / d, orally ; Aspirin , 100mg / times, 1 times / d; benazepril , 10mg / times, 1 times / d; atorvastatin statins , 10mg / times, 1 times / d; isosorbide mononitrate , 40rag / times, 1 times / d. Treatment group of 36 patients breviscapine 20mL plus 5 % glucose injection 250mL, infusion, 1 / d; Shenfu 50mL plus 5 % glucose injection 250mL, infusion, 1 times / d. Western medicine with the control group. 14d is a continuous course of treatment . Clinical symptoms , ECG , BNP improve the situation and the occurrence of cardiovascular events （ including angina worsening aggravated rehospitalization , myocardial infarction , death ） . A course of treatment to determine efficacy. 3-month follow-up were compared readmission trips and trips recurrence of symptoms . [ Results ] 18 cases markedly effective in 14 cases , 4 cases , the total efficiency of 88.89%. In the control group were 9 cases, effective in 20 cases, seven cases , the total efficiency of 80.56% . Treatment group than the control group （ P〈0.05 ） . BNP were improved in both groups （ P〈0.05 ）, improvement in the treatment group than the control group （ P〈0.05 ） . Readmission within 3 months of follow-up visits and trips recurrence of symptoms treatment group than the control group （P〈0.05） . [ Conclusion ] Breviscapine joint Shenfu Yang Qi decline treatment acute coronary syndrome, the effect is significant , adverse reactions , should be introduced.